Market Research Logo

Indolent Lymphoma - Pipeline Review, H2 2015

Indolent Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Indolent Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Indolent Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Indolent Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Indolent Lymphoma Overview
Therapeutics Development
Pipeline Products for Indolent Lymphoma - Overview
Pipeline Products for Indolent Lymphoma - Comparative Analysis
Indolent Lymphoma - Therapeutics under Development by Companies
Indolent Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Indolent Lymphoma - Products under Development by Companies
Indolent Lymphoma - Companies Involved in Therapeutics Development
AbbVie Inc.
Altor BioScience Corporation
Astellas Pharma Inc.
Bayer AG
Biothera, Inc.
Boehringer Ingelheim GmbH
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
Kite Pharma, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
MorphoSys AG
Indolent Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-803 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bendamustine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-836826 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DI-B4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duvelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
entospletinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imprime PGG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-39110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-40093 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-50465 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JCAR-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KTE-C19 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-0680 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-551 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-551 + MEDI-0680 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOR-208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
obinutuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Indolent Lymphoma - Recent Pipeline Updates
Indolent Lymphoma - Dormant Projects
Indolent Lymphoma - Discontinued Products
Indolent Lymphoma - Product Development Milestones
Featured News & Press Releases
Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting
Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH)
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Indolent Lymphoma, H2 2015
Number of Products under Development for Indolent Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Indolent Lymphoma - Pipeline by AbbVie Inc., H2 2015
Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H2 2015
Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015
Indolent Lymphoma - Pipeline by Bayer AG, H2 2015
Indolent Lymphoma - Pipeline by Biothera, Inc., H2 2015
Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Indolent Lymphoma - Pipeline by Celgene Corporation, H2 2015
Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015
Indolent Lymphoma - Pipeline by Incyte Corporation, H2 2015
Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2015
Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015
Indolent Lymphoma - Pipeline by MedImmune, LLC, H2 2015
Indolent Lymphoma - Pipeline by Merck & Co., Inc., H2 2015
Indolent Lymphoma - Pipeline by Merck KGaA, H2 2015
Indolent Lymphoma - Pipeline by MorphoSys AG, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
Indolent Lymphoma - Dormant Projects, H2 2015
Indolent Lymphoma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Indolent Lymphoma, H2 2015
Number of Products under Development for Indolent Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report